Health-Related Quality of Life as Measured by the 36-Item Short Form Survey Among Adults With Acute Bacterial Skin and Skin Structure Infections who Received Either Omadacycline or Linezolid in a Phase 3 Double-Blind, Double-Dummy Clinical Trial

Surya Chitra,1 Jordan Hinahara,2 Thomas F. Goss,3 Kyle Gunter,1 and Kenneth LaPensee4

1Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA, and 2Boston Healthcare Associates, Inc., Boston, Massachusetts, USA

This analysis of data from a Phase 3 study of adults with acute bacterial skin and skin structure infections showed that successful oral treatment with omadacycline (n = 368) or linezolid (n = 367) was associated with improvement in health-related quality of life.

Keywords. omadacycline; patient-reported outcome measures; acute bacterial skin and skin structure infections; ABSSSI; quality of life.

Omadacycline is an aminomethylcycline antibiotic that is approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired bacterial pneumonia in adults [1–3]. Omadacycline has demonstrated activity against many common pathogens involved in ABSSSIs, including Staphylococcus aureus and Streptococcus pyogenes [4, 5]. The efficacy and safety of omadacycline for adults with ABSSSIs were established in 2 Phase 3 studies, OASIS-1 (NCT02378480) and OASIS-2 (NCT02877927) [6, 7]. The US Food and Drug Administration (FDA) stipulates that outcome measures for registrational studies should be “direct measures or established surrogates of how patients feel or function” [10], and the 36-item Short Form Health Survey, version 2 (SF-36v2; Optum Inc., Minneapolis, MN, USA) [11, 12], a validated PRO health-related quality of life (HRQoL) measure [13], was prospectively incorporated in OASIS-2. The SF-36 has been included previously in study protocols to evaluate HRQoL in patients receiving antibiotic therapy for infections, including skin infections [14–16]. However, we are not aware of any studies of antibiotics that have demonstrated an association between clinical response (clinical success or clinical failure) and improvement in HRQoL, as measured by SF-36 score.

This post hoc exploratory analysis was performed to assess HRQoL outcomes as measured by the SF-36v2 in the OASIS-2 trial of patients randomized to oral omadacycline or oral linezolid treatment for ABSSSIs, overall and by clinical efficacy outcome.

METHODS

Study Design

OASIS-2 was a registrational Phase 3 clinical study comparing oral omadacycline with oral linezolid for treating adults with ABSSSIs. Clinical assessment of the infection site included the size of the primary lesion and microbiological assessment by gram stain and culture [7]. Patients were eligible for enrollment if they were aged ≥18 years, had a qualifying ABSSSI with primary lesion size ≥75 cm², and had evidence of systemic inflammatory response within 24 hours before randomization [7]. Eligible patients were randomized 1:1 to receive either omadacycline or linezolid stratified by type of infection (wound infection, cellulitis/erysipelas, and major abscess) and receipt of a single antibiotic dose within 72 hours before dosing [7]. Dosing and administration requirements for the study drug are included in the Supplementary Data (Supplementary Table 1). Clinical assessment of the infection site included the size of the primary lesion and microbiological assessment by gram stain and culture [7].

Health-Related Quality of Life

Patients completed the SF-36v2 questionnaire at the screening (baseline) visit and the post-therapy evaluation (PTE) visit (occurring between days 14 and 28). The SF-36v2 comprises 36 items assessing overall physical and mental health, including questions measuring health across 8 domains (Physical Functioning, Role–Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role–Emotional, and Mental Health) and 2 psychometrically based component summary scores, a Physical Component Summary and Mental

Received 22 January 2021; editorial decision 31 August 2021; accepted 7 September 2021.

Correspondence: Kyle Gunter, PharmD, Paratek Pharmaceuticals, Inc., 1000 First Avenue, Suite 200, King of Prussia, PA 19406 (kyle.gunter@paratekpharma.com).

Open Forum Infectious Diseases ©2021

© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

https://doi.org/10.1093/ofid/ofab459
Component Summary [11, 12, 17]. Responses to each item within a domain are combined to generate a scaled score from 0 to 100, where 100 indicates the best possible health. The mapping of individual items to the overall scale structure is summarized in Supplementary Figure 1 [11, 12].

**Patient Consent**
All clinical trial participants provided written informed consent.

**Data Analyses**
Descriptive analyses of patient demographics and baseline characteristics were conducted. Results of the SF-36v2 were analyzed in accordance with established norm-based standards for the survey [12]. No prespecified analysis plan for these data was developed before initiation of the study. A post hoc exploratory analysis was performed on the survey responses for the intent-to-treat (ITT) population (all randomized patients), overall and by clinical outcome. Due to the signficant proportion of persons who inject drugs (PWID) in the OASIS-2 study, a subgroup analysis was also performed to assess the HRQoL impact of treatment in PWID.

The change from baseline for each scaled score was analyzed using an analysis of covariance model with treatment group as a fixed effect and baseline scaled score as a covariate. Least-squares mean differences, corresponding 95% CIs, and P values were obtained using this model.

**RESULTS**
In total, 735 patients were enrolled in OASIS-2, and demographics and baseline characteristics in the ITT population were broadly similar between the 2 treatment groups, although a history of diabetes mellitus was reported in a higher percentage of patients in the linezolid group (8.7%, vs 4.1% in the omadacycline group) (Supplementary Table 2). Overall, most patients were male (462/735 [63%]) and White (668/735 [91%]). Injection drug use was the most common comorbid condition among OASIS-2 patients, and 69% of the ABSSSIs in the study were reported to be related to injection drug use [7].

Of the 735 patients enrolled in the study, 719 (361 in the linezolid group and 358 in the omadacycline group) fully completed the survey at baseline and 632 (316 in both groups) fully completed the survey at PTE. The lower number of completed surveys at PTE was due to loss to follow-up as well as incomplete surveys. Among all patients, irrespective of clinical outcome, baseline scores (data not shown) and changes from baseline to PTE follow-up in SF-36v2 mean scores were similar between the omadacycline and linezolid groups (Figure 1; Supplementary Table 3). Scores improved across all domains for the omadacycline group, and for all domains except General Health and Role–Emotional for the linezolid group (Figure 1; Supplementary Table 3). No statistically significant difference in the changes in mean domain scores or component summary scores was seen between omadacycline and linezolid in the ITT population (Figure 1). The Physical Component Summary score showed a statistically significant improvement from baseline for both treatment groups (Figure 1). At baseline, the SF-36 scores for both treatment groups were consistently lower than normative scores for the US population, most notably for the Bodily Pain domain (Supplementary Figure 2) [12]. When treatment groups were combined, among both PWID and non-PWID there was a substantial improvement from baseline in the Physical Component Summary score, similar to the overall patient population (Supplementary Table 3).

An additional analysis was performed for data pooled across treatment groups for the effect by clinical outcome (Table 1). In patients who had clinical success, regardless of treatment group, statistically significant improvements from baseline to PTE were reported in 6 of the 8 domains of the SF-36v2 survey and the Physical Component Summary score (Table 1). There was a small, nonsignificant decrease in the Mental Component Summary score from baseline to follow-up in patients with clinical success (Table 1). Patients with clinical failure had similar baseline scores (data not shown) as those with clinical success; however, no significant changes in SF-36v2 scores from baseline to PTE were seen in the pooled group of patients who had clinical failure (Table 1).

**DISCUSSION**
There is much interest in the “voice” of the patient in medical decision-making processes [18, 19], and one gap in current registrational ABSSSI studies is understanding what is most important to the patient [8]. Reduction in lesion size is used as a surrogate end point for registrational studies, substituting for an end point that is a direct measure of how a patient feels [10]. PROs can increase clarity and precision when interpreting end points for clinical meaningfulness [10]. Although it is likely to have been an assumption in previous studies, we believe that the current study is the first to report an observed difference for improvement in HRQoL, as measured by the SF-36v2, in patients who received antibiotic treatment for ABSSSI and had clinical success, as opposed to those with failure. As omadacycline and linezolid are both highly efficacious antibiotics in ABSSSIs, these data indicate that effective clinical treatment of ABSSSIs can be expected to improve HRQoL in this patient population. Baseline domain scores were lower than the US normative population, suggesting substantial QOL burden in ABSSSI before treatment [12]. While there were slight numerical improvements in summary scores for the clinical failure group from baseline to follow-up, no statistically significant change in HRQoL scale scores was observed in this group, potentially due to a type II error given the small number of patients in that group. To better understand how patients feel and whether this is associated with their clinical outcome, consideration of
patient-reported factors such as HRQoL should be explored further in future clinical trials.

OASIS-2 demonstrated that the oral antibiotics omadacycline and linezolid can treat significant ABSSSI (omadacycline: median lesion size [interquartile range {IQR}], 322 [198–495] cm²; linezolid: median lesion size [IQR], 294 [190–462] cm²) without hospitalization [7]. Clinical failure rates reported with omadacycline and linezolid were relatively low, at 7% and 9%, respectively [7]. Given the findings of the current analysis, that patients with clinical failure had a nonsignificant improvement in quality of life, real-world use studies and future guidelines should incorporate this knowledge, along with available efficacy, safety, antibiotic resistance rates, and economic data, to provide empiric treatment recommendations that allow many patients to receive appropriate therapy and minimize intravenous therapy and hospitalizations when possible.

PWID are a vulnerable population at high risk of ABSSSIs [20, 21]; PWID constituted a substantial proportion of the patients in OASIS-2 [7]. In the current analysis, PWID in both treatment groups showed improvement in HRQoL scores, which suggests that they can benefit from efficacious antibiotic therapy. However, as the number of patients with clinical failure was small, it was not possible to perform an analysis of changes in HRQoL by clinical outcome for the PWID subpopulation. Incorporating PROs in future studies may provide additional insights.

Several limitations should be considered when interpreting these data. There is no FDA-recommended HRQoL measure for ABSSSI treatment. General HRQoL questionnaires such as SF-36v2 are widely used and well validated, but the impact of antibiotic treatment on patient-reported HRQoL in ABSSSI is not. Furthermore, there is no universally accepted definition of what constitutes a clinically meaningful difference in HRQoL research for ABSSSI; this should be defined in future studies. It is unclear whether an HRQoL tool such as the SF-36v2, which uses a 4-week look-back period, is the most appropriate instrument for an acute illness like ABSSSI. The OASIS-2 study was not specifically designed or powered to assess HRQoL outcomes, and the analyses reported here were post hoc exploratory analyses; given the small number of patients with clinical failure, further

| SF-36v2 domains         | Omadacycline Change From Baseline (95% CI) | Linezolid Change From Baseline (95% CI) | Mean Treatment Difference (95% CI) | P Value |
|-------------------------|-------------------------------------------|-----------------------------------------|-----------------------------------|--------|
| Physical functioning    | 9.44 (6.76 to 12.13)                      | 7.58 (4.88 to 10.28)                   | 1.86 (–1.95 to 5.67)              | .34    |
| Role-physical           | 6.09 (3.64 to 8.53)                       | 2.96 (0.50 to 5.42)                    | 3.13 (–0.34 to 6.60)              | .08    |
| Bodily pain             | 9.77 (7.37 to 12.17)                      | 8.31 (5.89 to 10.72)                   | 1.46 (–1.94 to 4.87)              | .40    |
| General health          | 1.52 (–0.33 to 3.37)                      | –0.46 (–2.30 to 1.37)                  | 1.98 (–0.63 to 4.59)              | .14    |
| Vitality                | 2.19 (0.46 to 3.92)                       | 0.97 (–0.77 to 2.71)                   | 1.22 (–1.23 to 3.68)              | .33    |
| Social functioning      | 3.21 (0.92 to 5.50)                       | 3.04 (0.74 to 5.34)                    | 0.17 (–3.08 to 3.41)              | .92    |
| Role-emotional          | 2.88 (0.34 to 5.42)                       | –0.30 (–2.86 to 2.25)                  | 3.18 (–0.42 to 6.78)              | .08    |
| Mental health           | 2.05 (0.32 to 3.78)                       | 1.09 (–0.65 to 2.83)                   | 0.96 (–1.50 to 3.42)              | .44    |

**Figure 1.** Changes in SF-36v2 domain and component summary scores from baseline to post-therapy evaluation follow-up in patients in the omadacycline and linezolid treatment groups, irrespective of clinical outcome. All values are for the intent-to-treat population and are reported as mean (95% CI). Post-therapy evaluation follow-up occurred at 7–14 days after the last dose of study treatment. SF-36v2 scores at baseline and post-therapy evaluation follow-up are shown in Supplementary Table 3. Abbreviation: SF-36v2, 36-item Short Form Health Survey, version 2.
analyses for covariates could not be performed. Possible contributors to treatment failure and lower HRQoL could extend beyond antibiotic selection and resistance to include patient comorbidities, disease severity, surgical interventions, baseline lesion size, or lower baseline HRQoL [22]. Future studies should include relevant multivariate analyses to account for any confounding factors in the data. It would also be worthwhile to examine in a larger patient population whether absolute baseline SF-36v2 scores were similar in patients with clinical success and patients with clinical failure, or if there were any differences. Additionally, the patients’ preinfection HRQoL scores were unknown; it may be useful to determine in future studies if HRQoL scores are restored after treatment. The data used for the current analysis were obtained in the environment of a Phase 3 study in which these and other possible contributory factors were monitored and controlled. The differences in patient-reported, treatment-associated HRQoL identified here warrant further investigation, particularly in real-world studies, including when treating ABSSSI with antibiotics to which causative pathogens, such as S. pyogenes and S. aureus, have notable resistance and documented failure rates.

CONCLUSIONS

This exploratory analysis of HRQoL data collected in the OASIS-2 Phase 3 clinical trial suggests that, in patients with ABSSSI, those who achieve clinical success have a significant improvement in HRQoL and those with clinical failure do not. As stipulated in FDA guidance [8], clinical studies should aim to measure how a patient feels and functions, and patient-reported factors such as HRQoL may be useful to capture the “voice” of the patient, in addition to surrogate outcomes such as lesion size, hospital readmission rates, and safety.

Supplementary Data

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
Acknowledgments

Financial support. This study was funded by Paratek Pharmaceuticals, Inc. Medical editorial assistance, funded by Paratek Pharmaceuticals, Inc., was provided by Felicity Leigh, PhD, of Innovative Strategic Communications, Inc. The authors thank the participants and investigators involved in the OASIS-2 study.

Potential conflicts of interest. Surya Chitra and Kyle Gunter are employees of Paratek Pharmaceuticals. Kenneth LaPensee was an employee of Paratek Pharmaceuticals at the time of this analysis. Thomas Goss and Jordan Hinahara, and Kyle Gunter contributed to the interpretation of the study data and writing and editing of this manuscript have been disclosed.

Author contributions. Surya Chitra performed the statistical analysis of the HQoL study data. Kenneth LaPensee, Thomas Goss, Jordan Hinahara, and Kyle Gunter contributed to the interpretation of the study data and writing and editing of this manuscript.

Patient consent. All clinical trial participants provided written informed consent.

Data availability. The primary study results have been published in Lancet Infectious Diseases [7] and are available at ClinicalTrials.gov (NCT02877927) and in the OASIS-2 clinical study report (Clinical Study Report: PTK0796-ABSI-16301).

References

1. Honeyman L, Ismail M, Nelson ML, et al. Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline. Antimicrob Agents Chemother 2015; 59:7044–53.
2. Villano S, Steenbergen J, Loh E. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections. Future Microbiol 2016; 11:1421–34.
3. Paratek Pharmaceuticals, Inc. NUZYRA (omadacycline) prescribing information. Revised October 2020. Available at: https://www.nuzyra.com/nuzyra-pi.pdf. Accessed December 2020.
4. Tanaka SK, Steenbergen J, Villano S. Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. Bioorg Med Chem 2016; 24:6409–19.
5. Macone AB, Caruso BK, Leahy RG, et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother 2014; 58:1127–35.
6. O’Riordan W, Green S, Overcash JS, et al. Omadacycline for acute bacterial skin and skin-structure infections. N Engl J Med 2019; 380:528–38.
7. O’Riordan W, Cardenas C, Shin E, et al; OASIS-2 Investigators. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. Lancet Infect Dis 2019; 19:1080–90.
8. Talbot GH, Powers JH, Fleming TR, et al; CABP-ABSSSI Project Team. Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. Clin Infect Dis 2012; 55:1114–21.
9. US Food and Drug Administration. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. 2013. Available at: http://www.fda.gov/downloads/Drugs/Guidances/ucm071185.pdf. Accessed 20 May 2021.
10. Powers JH 3rd, Howard K, Saretsky T, et al. Patient-reported outcome assessments as endpoints in studies in infectious diseases. Clin Infect Dis 2016; 63(Suppl 2):S52–6.
11. Maruish ME, ed. User’s Manual for the SF-36v2 Health Survey. 3rd ed. QualityMetric Incorporated; 2011.
12. Ware JE Jr. SF-36 Health Survey update. Spine (Phila Pa 1976) 2000; 25:3130–9.
13. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 Health Survey questionnaire: new outcome measure for primary care. BMJ 1992; 305:160–4.
14. Cranendonk DR, Opmeer BC, Prins JM, Wiersinga WJ. Comparing short to standard duration of antibiotic therapy for patients hospitalized with cellulitis (DANCE): study protocol for a randomized controlled trial. BMC Infect Dis 2014; 14:235.
15. Quirke M, Wakai A, Gilligan P, O’Sullivan R. Oral flucloxacillin and phenoxymethylpenicillin versus flucloxacillin alone for the emergency department outpatient treatment of cellulitis: study protocol for a randomised controlled trial. Trials 2013; 14:164.
16. Midstone A, Patsimas J, Farzan D, et al; PROPer Use Study Group. Prospective observational study of patient-reported outcomes for azithromycin versus usual care in the treatment of bacterial acute exacerbation of chronic bronchitis. Clin Ther 2005; 27:926–39.
17. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31:247–63.
18. Stiggelbout AM, Van der Weijden T, De Wit MP, et al. Shared decision making: really putting patients at the centre of healthcare. BMJ 2012; 344:e256.
19. Brunelli C, Borreani C, Caraceni A, et al; PATIENT VOICES study group. PATIENT VOICES, a project for the integration of the systematic assessment of patient reported outcomes and experiences within a comprehensive cancer center: a protocol for a mixed method feasibility study. Health Qual Life Outcomes 2020; 18:252.
20. Serota DP, Chueng TA, Schechter MC. Applying the infectious diseases literature to people who inject drugs. Infect Dis Clin North Am 2020; 34:539–58.
21. Chambers HF. Skin and soft tissue infections in persons who inject drugs. Infect Dis Clin North Am 2021; 35:169–81.
22. Pulido-Cejaudo A, Guzmán-Gutierrez M, Jafie-Montaño A, et al. Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure. Ther Adv Infect Dis 2017; 4:143–61.